

Technical Meeting

Impact of COVID-19 on Cervical Cancer Screening, Treatment and Vaccination

12 - 13 November 2020

ANTWERP, BELGIUM

Key partners of the Covid-19 and Cancer Global Modelling Consortium.



HPV Prevention and Control Board



www.hpvboard.org

Mission, Goal & Objectives

1. Mission:

Generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders.

2. Goal:

Contribute to the control of HPV infection and to the prevention and screening of HPV related cancers.

3. Objectives:

Providing evidence based guidance on key technical and strategic issues.

Monitoring the progress of HPV control programs at the country and regional levels.



A multi-disciplinary Board formed by prominent experts (Advisors/Observers)

- Act in their personal capacity, and not as representatives of their institutions
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc : minimal bureaucratic structure
- Observers of several national and international organisations.



Supported by a permanent & dynamic Scientific Secretariat:

- Personnel involved*:
 - Brenda Janssens, Xenia Mikulla
 - Greet Hendrickx
 - Sara Valckx
 - Dur-e-Nayab Waheed
 - Alex Vorsters
- Executive Secretary: Pierre Van Damme




- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp

*: Total involvement of 2.0 FTE, all member have other tasks at the department.



Secretariat implements:

- Preparation and organisation of meetings
 - Publications
 - Media activities
 - Website: www.hpvboard.org
 - Participation in third party meetings
 - All financial issues are done by the rules of the University of Antwerp
-  Permanent intensive communication between HPV board members and secretariat



Home

About us

Meetings

Resources

Vaccine safety

News

You are here: ... > [Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward - Nc](#)

Meetings

> **Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward - November 2018**

> **Videos (EN)**

> Videos (ES)

> The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania - May 2018

> Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward - November 2017

Intro Video HPV Prevention & Control Board Meeting - Bogota, Colombia 2018

SESSION 1: OPENING & OBJECTIVES

Speech #1 by Vice Minister of Health, Ivan Dario Gonzalez - (EN)



Technical Meeting

Impact of Covid-19 on Cervical Cancer Screening, Treatment and Vaccination

12 - 13 November, 2020
Antwerp, Belgium

BACKGROUND DOCUMENT

PRE-MEETING-DRAFT

Meeting participants invited to provide input/comments

Dur-e-Nayab Waheed and Alex Vorsters
HPV Prevention & Control Board

Executive Secretariat, Vaccine and Inevitable disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Antwerpen, Belgium.

1

Please note that this is a draft version. The final version will be available on the website after meeting. Comments can be addressed to Nayab.Waheed@uantwerpen.be

Content

Introduction.....	3
Purpose of the background document	4
Part 1: References based on a Pubmed search, by Topic.....	10
Impact of Covid-19 on HPV Vaccination	11
HPV Screening and Treatment; Opportunities and Challenges in different regions.....	14
Cervical Cancer Prevention and Control Covid-19 Updated Guidelines.....	20
Modelling strategies to support decision making and make better health interventions	27
Turning impact of Covid-19 into pathway for innovation.....	28
Part 2: Bibliography of Speakers	30
Alejandra Castanon, Senior Epidemiologist, King's College London.....	31
Lucia Yin ling Woo, Professor of Obstetrics and Gynaecology, Consultant Gynaecological Oncologist, University of Malaya.....	31
Lucia Helena de Oliveira, Regional Advisor on Immunization, PAHO/WHO.....	32
Victor Bertollo, Consultant, National Immunization Program, Brazilian Ministry of Health.....	33
Tania Cernuschi, Team Lead – Global Access, World Health Organisation (WHO).....	34
Marc Arbyn, Scientific Institute of Public Health (Belgium).....	34
Murat Gultekin, ¹ Prof. / Chair of National HPV Screening Program of Turkey and Ex.....	34
Emily Burger, Research Scientist (Harvard), Associate Professor (University of Oslo), Harvard T.H. Chan School of Public Health and the University of Oslo Department of Health Management and Health Economics.....	35

2


Please note that this is a draft version. The final version will be available on the website after meeting. Comments can be addressed to Nayab.Waheed@uantwerpen.be



COVID-19 and Cancer Global
Modelling Consortium

ccgmc.org

260+ participants
38 countries
165 institutions



International Agency for Research on Cancer



Policy-relevant questions driving the CCGMC activities

- What is the quantified impact of the long term impact of the crisis on cancer outcomes?
 - How does this supplement our understanding of the full (not just the acute) health impact of the crisis?
- What are the optimal mitigation/recovery strategies after disruption?
 - How should finite resources be prioritised in the recovery (e.g. limited colposcopy or treatment services capacity)
- What is the potential impact and cost-effectiveness of the accelerated adoption of innovative recovery strategies or new technologies (i.e. ‘silver linings’)?



Technical Meeting

Impact of COVID-19 on Cervical Cancer Screening, Treatment and Vaccination

12 - 13 November 2020

ANTWERP, BELGIUM

Meeting objectives (1):

- **Update on Covid-19 pandemic: What's the new normal?**
- **Discuss impact of Covid-19 on WHO cervical elimination goals**
- **Impact of Covid 19 on Vaccination**
 - Discuss current situation of vaccination programs across different regions in the world.
 - Discuss impact of Covid-19 on school-based vaccination programs and the strategies to restart the programs.
 - Vaccine implementation in LMICS and coverage in HICs.
 - Impact of Covid-19 on vaccine clinical trials; country examples with ongoing trials, challenges, and strategies to proceed forward.
 - Discuss how vaccine supply shortage situation will evolve due to the pandemic.



Meeting objectives (2):

- **Impact of Covid-19 on HPV Screening and Treatment**
 - Discuss current situation of screening and treatment programs across different regions in the world.
 - Identify successful programs such as ROSE in Malaysia to discuss how Covid has impacted these programs their adapted strategies and what is the way forward.
 - Discuss self-sampling as an alternate strategy.
 - Discuss strategies to restart screening and treatment in HICs and LMICS.
 - Discuss supply shortage of HPV assays.
 - HPV assays validation in Covid-19 times; current prospect and challenges.
 - Impact of Covid-19 on HPV screening and treatment Clinical trials ; country examples with ongoing trials , challenges, and strategies to proceed forward.
 - Discuss modelling strategies to support decision making: What are the information needs for developing robust and accurate models of pandemic impacts.
 - Reviewing cervical cancer control disruptions in various countries and assess impact of Covid-19 on vaccination, screening and treatment.



Meeting objectives (3):

- **Discuss modelling strategies to support decision making**
 - Using modelling expertise to determine the intermediate and long term impact of disruptions
 - Using modelling to inform decision-making for optimizing mitigation and recovery strategies.
- **Turning the impact of COVID-19 into a positive pathway for innovation**
 - Discuss how Covid-19 can be used as an opportunity to bring more robust techniques to deal with screening and vaccination challenges i.e. mobile clinics, self-sampling, mobile apps, more innovative approaches.

